William Ondo, MD
Neurology · Houston, TXNPI 1851471437
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $931,630 of the $1,372,112 with a category attached, or 67.9%. 57 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 27.7% of the total. Among neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,106 payments — averaging $651.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$380K
- Teva Pharmaceuticals USA, Inc.$173K
- Acadia Pharmaceuticals Inc$156K
- MDD US Operations, LLC$150K
- AbbVie$113K
- Acorda Therapeutics, Inc$105K
- plus $294K from 51 others
Across 78 payments — averaging $21,845 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$1.2M
- Amneal Pharmaceuticals LLC$193K
- Sunovion Pharmaceuticals Inc.$104K
- Lundbeck LLC$90K
- AbbVie$79K
- Eli Lilly$20K
- plus $3K from 2 others
What the payments were for
- Consulting fees$293,26221%
- Speaking & faculty fees$931,63068%
- Travel & lodging$95,3147%
- Food & beverage$42,2643%
- Education$9,6411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,372,112 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 495 | $760,791 |
| NuplazidPimavanserin Tartrate | 119 | $743,694 |
| GocovriAmantadine Hcl | 112 | $395,855 |
| AustedoDeutetrabenazine | 50 | $364,830 |
| IngrezzaValbenazine Tosylate | 39 | $316,103 |
| Austedo XrDeutetrabenazine | 26 | $214,911 |
| NourianzIstradefylline | 41 | $130,810 |
| BotoxOnabotulinumtoxina | 81 | $97,320 |
| NeuproRotigotine | 60 | $81,952 |
| OngentysOpicapone | 69 | $66,360 |
| HorizantGabapentin Enacarbil | 44 | $64,903 |
| Rasagiline Mesylate | 237 | $40,068 |
| BelbucaBuprenorphine Hcl | 43 | $36,565 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $30,249 |
| BelsomraSuvorexant | 22 | $18,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $98,999 | $760,791495 claims |
| Acadia Pharmaceuticals IncNuplazid | $155,751 | $743,694119 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $173,063 | $579,74176 claims |
| MDD US Operations, LLCGocovri | $150,243 | $395,855112 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $380,351 | $382,462108 claims |
| Kyowa Kirin, Inc.Nourianz | $63,903 | $130,81041 claims |
| AbbVieBotox | $113,333 | $97,32081 claims |
| UCB, Inc.Neupro | $1,563 | $81,95260 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $193 | $64,90344 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $65 | $36,56543 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $54 | $30,24920 claims |
| Merz North America, Inc.Xeomin | $204 | $13,96414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.
Other neurology in Houston
- Pankaj SatijaHouston$1.1M
- Annette HowardHouston$826K
- Randolph EvansHouston$493K
- Leorah FreemanHouston$401K
- Mazen DimachkieHouston$388K
- Zsila SadighiHouston$361K
- Joseph JankovicHouston$323K
- Raja MehannaHouston$300K
- Eddie PattonHouston$299K
- Nicolas NammourHouston$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.